Journal
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
Volume 61, Issue 2, Pages 160-173Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ajhp/61.2.160
Keywords
amitriptyline; analgesics and antipyretics; anticonvulsants; antidepressants; antiinflammatory agents; antioxiclants; antiparkinson agents; antitussives; bupropion; caffeine; capsaicin; cardiac drugs; central nervous system stimulants; citalopram; classification; clonidine; desipramine; dextromethorphan; diabetic neuropathies; dihydroergotamine; enzyme inhibitors; epidemiology; erythromycin; fludrocortisone; fluoxetine; gabapentin; gastrointestinal drugs; hypotensive agents; lamotrigine; levodopa; macrolides; metoclopramide; mexiletine; midodrine; octreotide; opiates; oxcarbazepine; paroxetine; phenytoin; ruboxistaurin; steroids; cortico-; sympatholytic agents; sympathomimetic agents; thioctic acid; tramadol; transcutaneous electric nerve stimulation; venlafaxine; zonisamide
Categories
Ask authors/readers for more resources
Purpose. The epidemiology, classification, pathology, and treatment of diabetic neuropathy are reviewed. Summary. Diabetic peripheral neuropathy is a common complication of diabetes that can cause significant morbidity and mortality. Some 30% of hospitalized and 20% of community-dwelling diabetes patients have peripheral neuropathy; the annual incidence rate is approximately 2%. The primary risk factor is hyperglycemia. Sensorimotor neuropathy is marked by pain, paresthesia, and sensory loss. Cardiac autonomic neuropathy (CAN) may contribute to myocardial-infarction, malignant arrhythmia, and-sudden death. Gastroparesis is the most debilitating complication of gastrointestinal autonomic neuropathy. Genitourinary autonomic neuropathy can cause sexual dysfunction and neurogenic bladder. The pathology of diabetic neuropathy involves oxidative stress, advanced glycation end products; polyol pathway flux, and protein kinase C activation; all contribute to microvascular disease and nerve dysfunction. For symptom management current evidence from clinical trials supports the use of desipramine, amitriptyline, capsaicin, tramadol, gabapentin, bupropion, and venlafaxine as preferred medications. Citalopram, nonsteroidal antiinflammatory drugs, and opioid analgesics may be used as adjuvant agents. Lamotrigine, oxcarbazepine, paroxetine, levodopa, and alpha-lipoic acid are alternatives considerations. Evidence supporting the use of zonisamide, fluoxetine, mexiletine, dextromethorphan, and phenytoin is considered equivocal. Complementary therapies have also shown efficacy. The symptoms of CAN may be ameliorated with fludrocortisone, clonidine, midodrine, dihydroergotamine or caffeine, octreotide, and beta-blockers. Gastroparesis may be treated with metoclopramide or erythromycin. The most promising disease-modifying therapy is ruboxistaurin, which is in Phase III trials. Glycemic control remains the foundation of prevention and the prerequisite of adequate treatment. Conclusion. Diabetic neuropathy is a many-faceted complication of diabetes that can be managed symptomatically with an array of drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available